Obesity influences outcome of sentinel lymph node biopsy in early-stage breast cancer

被引:73
作者
Derossis, AM [1 ]
Fey, JV [1 ]
Cody, HS [1 ]
Borgen, PI [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
关键词
D O I
10.1016/j.jamcollsurg.2003.08.005
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Sentinel lymph node biopsy is a rapidly emerging standard of care for staging the axilla in invasive breast cancer. Factors influencing success must be identified to understand the procedure's limitations and challenges. Increasing body mass with age has an inverse relationship to success. A proportion of SLN biopsy patients are both senior and overweight, so measurement of the body mass to age relationship is essential. STUDY DESIGN: We reviewed mapping successes and failures in 2,495 SLN biopsy procedures performed between September 1996 and June 2001. Clinical stage T I NO to T3 NO breast cancer cases were included. We used a combined technique (radioisotope and blue dye) to detect SLNs. Failure was defined as the inability to identify any nodes with either blue dye or by in vivo counts. Body-mass index (BMI) for each patient was measured by height and weight data (kg/m(2)), and cases were stratified by BMI and age. RESULTS: Among 2,495 cases, there were 62 failed and 2,433 successful mappings (failure rate = 2.48%). Mean age, weight, and BMI were significantly higher in the failure group. The success of SLN biopsy was inversely related to BMI (r = -0.98, p = 0.002). When stratified by patient age (< 50 versus greater than or equal to50 years), this relationship was more pronounced in the ! 50 group. Multivariate analysis of age, weight, and BMI found age (p = 0.011) and BMI (p = 0,0000 1) to be predictive of SLN mapping success, with weight alone not significant. CONCLUSIONS: Increasing age and BMI do not appear to be contraindications for SLN biopsy. Rather, surgeons should be aware that increasing body mass and age are potential risk factors for a failed procedure, in which case a completion axillary node dissection for staging is required. (C) 2003 by the American College of Surgeons.
引用
收藏
页码:896 / 901
页数:6
相关论文
共 31 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]  
[Anonymous], 1998, CLIN GUID ID EV TREA
[3]  
CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO
[4]  
2-I
[5]  
*CDC NAT CTR STAT, 1997, NAT HLTH INT SURV
[6]   Complementarity of blue dye and isotope in sentinel node localization for breast cancer: Univariate and multivariate analysis of 966 procedures [J].
Cody, HS ;
Fey, J ;
Akhurst, T ;
Fazzari, M ;
Mazumdar, M ;
Yeung, H ;
Yeh, SDJ ;
Borgen, PI .
ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (01) :13-19
[7]   Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer [J].
Cox, CE ;
Pendas, S ;
Cox, JM ;
Joseph, E ;
Shons, AR ;
Yeatman, T ;
Ku, NN ;
Lyman, GH ;
Berman, C ;
Haddad, F ;
Reintgen, DS .
ANNALS OF SURGERY, 1998, 227 (05) :645-653
[8]  
Cox Charles E, 2002, Breast J, V8, P88, DOI 10.1046/j.1524-4741.2002.08203.x
[9]   A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer [J].
Derossis, AM ;
Fey, J ;
Yeung, H ;
Yeh, SDJ ;
Heerdt, AS ;
Petrek, J ;
VanZee, KJ ;
Montgomery, LL ;
Borgen, PI ;
Cody, HS .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2001, 193 (05) :473-478
[10]   Sentinel lymphadenectomy in breast cancer [J].
Giuliano, AE ;
Jones, RC ;
Brennan, M ;
Statman, R .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2345-2350